Estelle Berger

Company: 3T Biosciences

Job title: Cdo

Seminars:

Advancing Screening Methods for Both Targets & TCR Molecules to Boost Validation Strategy & Guarantee Patient Safety 9:05 am

Since TCR therapies have been known to cause off-target toxicities, it is vital for patient safety to ensure targets are localized and restricted to tumor cells, meanwhile TCRs are specific to antigen targets. Next-generation TCR and target screening methods and technologies can provide the optimal validation to prevent cross-reactivity and off-target effects to secure therapy…Read more

day: Pre-Conference Workshops